ArticleFrontiers in cardiovascular medicine2021
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.
Article in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Coronary Atherosclerosis in Outlier Subjects: Protective and Individual Risk Factor Evaluation
Cross-sectional Cohort Analysis of Plasma Proteomics in Coronary Artery Disease and Plasma Metabolomics in Coronary Artery Disease: Comparative Study Between Patients with Obstructive (≥ 50%), Non-obstructive (< 50%) and No Lesions
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Proteomic predictors of mortality among people with Coronary Artery Disease.American journal of preventive cardiology · 2025Article
- Interaction and biological pathway analysis of proteomic products in patients with premature coronary artery disease.Clinical proteomics · 2025Article
- Proteome-Wide Mendelian Randomization Identifies Candidate Causal Proteins for Cardiovascular Diseases.Advanced genetics (Hoboken, N.J.) · 2025Article
- Plasma proteomics improves prediction of coronary plaque progression.European heart journal. Cardiovascular Imaging · 2025Article
- Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease.Genome medicine · 2024Article
- A novel urinary proteomic classifier predicts the risk of coronary artery disease.European journal of preventive cardiology · 2023Article
- Coronary Artery Disease and Aortic Valve Stenosis: A Urine Proteomics Study.International journal of molecular sciences · 2022Article
- The role of cardiac computed tomography in predicting adverse coronary events.Frontiers in cardiovascular medicine · 2022Review
- Aptamer-based applications for cardiovascular disease.Frontiers in bioengineering and biotechnology · 2022Review
- Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.Expert review of cardiovascular therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProteomics of atypical phenotypes may help unravel cardiovascular disease mechanisms.
aimWe aimed to prospectively screen the proteome of four types of individuals: with or without coronary artery disease (CAD), each with or without multiple risk factors. Associations with individual risk factors and circulating biomarkers were also tested to provide a functional context to the protein hits. MATERIALS AND
methodsThe CAPIRE study (ClinicalTrials.gov Identifier: NCT02157662) is a cross-sectional study aimed at identifying possible new mechanisms promoting or protecting against atherothrombosis. Quantification (by aptamer technology), ranking (using partial least squares), and correlations (by multivariate regression) of ~5000 plasma proteins were performed in consecutive individuals aged 45-75 years, without previous cardiovascular disease, undergoing computed tomography angiography for suspected CAD, showing either >5/16 atherosclerotic segments (CAD
resultsOf 544 individuals, 39% were atypical (93 CAD
conclusionsIn a CCTA-based cohort, four proteins, involved in opposing vascular processes (healing vs. adverse remodeling), are specifically associated with low CAD burden in high CV-risk individuals (high MYO and C-C-22) and high CAD burden in low-risk subjects (high PS-3 and PAF-AH), in interaction with BMI, smoking, diabetes, HDL-cholesterol, and HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.